- Home
- NVO
NVO
Novo Nordisk A/S
as 07-26-2024 4:00pm EST
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 593.1B | IPO Year: | N/A |
| Target Price: | $140.50 | AVG Volume (30 days): | 4.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 2.90 | EPS Growth: | 47.44 |
| 52 Week Low/High: | $77.96 - $148.15 | Next Earning Date: | 08-07-2024 |
| Revenue: | $35,346,309,696 | Revenue Growth: | 29.72% |
| Revenue Growth (this year): | 26.45% | Revenue Growth (next year): | 20.82% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
MT Newswires
6 hours ago
US FDA Flags Overdosing of Novo Nordisk's Semaglutide in Patients
Yahoo Finance Video
7 hours ago
June PCE inflation print, auto earnings: Morning Brief
Pharmaceutical Technology
9 hours ago
EMA backs Wegovy cardiovascular label update as Novo seeks EU coverage
Zacks
9 hours ago
Is Eli Lilly's Stock in a Bubble?
Yahoo Finance Video
10 hours ago
EU approves Novo Nordisk's Wegovy for heart, stroke treatment
Zacks
12 hours ago
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
Motley Fool
a day ago
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Investopedia
a day ago
Why Viking’s Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk Stocks
Compare NVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.